GlassScriptPhysician profile
Richard N Frame
NPI 1073563516
$1,743.51
in general payments reported to CMS, 2019-2025
23 companies · $128 in 2025
The $128 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $369 · 2020: $828 · 2021: $44.38 · 2022: $116 · 2023: $151 · 2024: $107 · 2025: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $366 · Education: $19.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $366.13 |
| Education | $19.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $589.99 | 2020-2024 | Enhertu |
| Astrazeneca Pharmaceuticals LP | $242.84 | 2019-2020 | |
| Incyte Corporation | $129.18 | 2020 | |
| Janssen Biotech, INC. | $126.68 | 2019-2022 | |
| Rigel Pharmaceuticals, INC. | $111.38 | 2020 | |
| Foundation Medicine, INC. | $97.25 | 2019 | |
| Abbvie INC. | $58.67 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $52.00 | 2019 | |
| Eisai INC. | $38.56 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $38.10 | 2023 | Keytruda |
| Lilly USA, LLC | $36.89 | 2023-2025 | Verzenio, Jaypirca |
| Jazz Pharmaceuticals INC. | $36.70 | 2024-2025 | |
| Coherus Oncology, INC. | $36.44 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $24.89 | 2023 | Libtayo |
| Clovis Oncology, INC. | $20.36 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $19.42 | 2024 | |
| Puma Biotechnology, INC. | $16.71 | 2025 | |
| Seagen INC. | $15.49 | 2022 | |
| Astellas Pharma US INC | $15.49 | 2024 | Cresemba |
| Pfizer INC. | $12.86 | 2021 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Genzyme Corporation | $11.69 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$28,357.82 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Frame listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.